2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Venglustat GZ402671: new trials by email Literature Review of Venglustat GZ402671 trials Research Report on Venglustat GZ402671
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat Venglustat GZ402671 - Congenital Cystic Kidney Disease | Phase 3 | Terminated | Sanofi | 24 | 2021-02-09 | 2025-09-17 |
| A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2 venglustat GZ402671, placebo - Tay-Sachs Disease, Sandhoff Disease | Phase 3 | Terminated | Genzyme, a Sanofi Company | 75 | 2020-06-29 | 2026-01-28 |
Kidney Diseases, Cystic (1) · Sandhoff Disease (1) · Tay-Sachs Disease (1)
Genzyme, a Sanofi Company (1) · Sanofi (1)
Germany (2) · Japan (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Czechia (1) · France (1) · Italy (1) · Netherlands (1) · Portugal (1) · Russia (1) · South Korea (1)
2019 (1)